Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs

Journal of Controlled Release

Volumn 140, Issue 3, 2009, Pages 294-300

  Shin, Ho Chul ^a   Alani, Adam W G ^a   Rao, Deepa A ^b   Rockich, Nicole C ^a   Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b DRAKE UNIVERSITY   (United States)

Author keywords

Combination drug therapy; Cremophor EL; Drug solubilization; Heat shock protein 90 inhibitor; Polymeric micelle

Indexed keywords

ALLYLAMINO; ANTI-CANCER AGENTS; ANTICANCER DRUG; DOCETAXEL; DRUG COMBINATIONS; DRUG FORMULATIONS; DRUG LOADING; DRUG RELEASE; DRUG SOLUBILIZATION; ETOPOSIDE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IN-VITRO; PACLITAXEL; POLY(D , L-LACTIC ACID); POLYMERIC MICELLE; POORLY WATER-SOLUBLE DRUGS; SIDE EFFECT; STABILITY ISSUES;

DRUG INTERACTIONS; ELECTROLUMINESCENCE; ETHYLENE; ETHYLENE GLYCOL; LACTIC ACID; MICELLES; ORGANIC ACIDS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS; PROTEINS; SOLUBILITY;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG CARRIER; ETOPOSIDE; PACLITAXEL; POLY(ETHYLENE GLYCOL) BLOCK POLY(DEXTRO LACTIC ACID); TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; LIGHT SCATTERING; MICELLE; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GLYCEROL; HALF-LIFE; LIGHT; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; NEPHELOMETRY AND TURBIDIMETRY; POLYMERS; RATS; SCATTERING, RADIATION; SOLUBILITY;

EID: 70449711530     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.04.024     Document Type: Article

References (41)

1. Aliabadi H.M., Shahin M., Brocks D.R., and Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clinical Pharmacokinetics 47 (2008) 619-634
2. Kwon G.S. Editorial for theme section on polymeric micelles for drug delivery. Pharmaceutical Research 25 (2008) 2053-2055
3. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. Journal of Controlled Release 73 (2001) 137-172
4. Kataoka K., Kwon G.S., Yokoyama M., Teruo O., and Sakurai Y. Block copolymer micelles as vehicles for drug delivery. Journal of Controlled Release Special Issue Proceedings of the Second European Symposium on Controlled Drug Delivery 24 (1993) 119-132
5. Vakil R., and Kwon G.S. Poly(ethylene glycol)-b-poly(E-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 22 (2006) 9723-9729
6. Aliabadi H.M., Mahmud A., Sharifabadi A.D., and Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly([var epsilon]-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. Journal of Controlled Release 104 (2005) 301-311
7. Okuda T., Kawakami S., Yokoyama M., Yamamoto T., Yamashita F., and Hashida M. Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles in mice. International Journal of Pharmaceutics 357 (2008) 318-322
8. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Advanced Drug Delivery Reviews "Clinical Developments in Drug Delivery Nanotechnology" 60 (2008) 899-914
9. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Kim S.W., and Seo M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. Journal of Controlled Release 72 (2001) 191-202
10. Ravenelle F., Vachon P., Rigby-Jones A.E., Sneyd J.R., Le Garrec D., Gori S., Lessard D., and Smith D.C. Anaesthetic effects of propofol polymeric micelle: a novel water soluble propofol formulation. British Journal of Anaesthesia 101 (2008) 186-193
11. Forrest M.L., Won C.-Y., Malick A.W., and Kwon G.S. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly([epsilon]-caprolactone) micelles. Journal of Controlled Release 110 (2006) 370-377
12. Tije A.J.t., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clinical Pharmacokinetics 42 (2003) 665-685
13. Weiss R., Donehower R., Wiernik P., Ohnuma T., Gralla R., Trump D., Baker Jr. J., Van Echo D., Von Hoff D., and Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol 8 (1990) 1263-1268
14. Lorenz W., Reimann H.-J., Schmal A., Dormann P., Schwarz B., Neugebauer E., and Doenicke A. Histamine release in dogs by Cremophor EL ® and its derivatives: oxethylated oleic acid is the most effective constituent. Inflammation Research 7 (1977) 63-67
15. Dye D., and Watkins J. Suspected anaphylactic reaction to Cremophor EL. British Medical Journal 280 (1980) 1353
16. Solit D.B., Basso A.D., Olshen A.B., Scher H.I., and Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res 63 (2003) 2139-2144
17. Solit D.B., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., Teitcher J., Wolchok J.D., Germino F.J., Krown S.E., Coit D., Rosen N., and Chapman P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14 (2008) 8302-8307
18. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., and Hudis C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
19. Hennenfent K.L., and Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 17 (2006) 735-749
20. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. European Journal of Cancer 34 (1998) 1514-1521
21. Solit D.B., and Chiosis G. Development and application of Hsp90 inhibitors. Drug Discovery Today 13 (2008) 38-43
22. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.-B., Rha S.Y., Lee M.Y., and Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Research and Treatment 108 (2008) 241-250
23. R.S. Finley, C. Balmer, Optimizing chemotherapy outcome. In R.S. Finleyand C. Balmer (eds), Concepts in Oncology Therapeutics (R.S. Finleyand C. Balmer, eds), American Society of Health-System Pharmacists, Bethesda, MD, 1998, pp. 87-89.
24. Zhou Y., Feng L., Mueller T., Liu F., and Johnson Jr. R.G. 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: an effective approach for combination therapy. AACR Meeting Abstracts 2004 (2004) 458-b.
25. Xiao L., Rasouli P., and Ruden D.M. Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs. Current Medicinal Chemistry 14 (2007) 223-232
26. Munster P.N., Basso A., Solit D., Norton L., and Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clinical Cancer Research 7 (2001) 2228-2236
27. Nguyen D.M., Chen A., Mixon A., Schrump D.S., and Roth S.J.A. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. Journal of Thoracic and Cardiovascular Surgery 118 (1999) 908-915
28. Sain N., Krishnan B., Ormerod M.G., De Rienzo A., Liu W.M., Kaye S.B., Workman P., and Jackman A.L. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics 5 (2006) 1197-1208
29. Nguyen D.M., Lorang D., Chen G.A., Stewart J.H., Tabibi E., and Schrump D.S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. The Annals of Thoracic Surgery 72 (2001) 371-379
30. Ramalingam S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., Chatta G.S., Friedland D.M., Stoller R.G., Potter D.M., Ivy S.P., and Belani C.P. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 14 (2008) 3456-3461
31. Barker C.R., Hamlett J., Pennington S.R., Burrows F., Lundgren K., Lough R., Watson A.J.M., and Jenkins J.R. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?. International Journal of Cancer 118 (2006) 2685-2693
32. Yao Q., Weigel B., and Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clinical Cancer Research 13 (2007) 1591-1600
33. Hawkins L.M., Jayanthan A.A., and Naredran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric Research 57 (2005) 430-437
34. Xiong M.P., Yanez J.A., Kwon G.S., Davies N.M., and Laird Forrest M. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. Journal of Pharmaceutical Sciences 98 (2009) 1577-1586 10.1002/jps.21509
35. Ali S.M., Hoemann M.Z., Aube, Jeffrey, Georg G.I., Mitscher L.A., and Jayasinghe L.R. Butitaxel analogues: synthesis and structure-activity relationships. Journal of Medicinal Chemistry 40 (1997) 236-241
36. Lee S.C., Huh K.M., Lee J., Cho Y.W., Galinsky R.E., and Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules 8 (2007) 202-208
37. Thomas S., Brightman F., Gill H., Lee S., and Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. Journal of Pharmaceutical Sciences 97 (2008) 4557-4574
38. Tian Z.-Q., Liu Y., Zhang D., Wang Z., Dong S.D., Carreras C.W., Zhou Y., Rastelli G., Santi D.V., and Myles D.C. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorganic & Medicinal Chemistry 12 (2004) 5317-5329
39. Blanco E., Bey E.A., Dong Y., Weinberg B.D., Sutton D.M., Boothman D.A., and Gao J. [Beta]-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. Journal of Controlled Release "Proceedings of the Thirteenth International Symposium on Recent Advances in Drug Delivery Systems" 122 (2007) 365-374
40. Heald C.R., Stolnik S., Kujawinski K.S., De Matteis C., Garnett M.C., Illum L., Davis S.S., Purkiss S.C., Barlow R.J., and Gellert P.R. Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona. Langmuir 18 (2002) 3669-3675
41. Chen H., Kim S., He W., Wang H., Low P.S., Park K., and Cheng J.-X. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging. Langmuir 24 (2008) 5213-5217